TUMOR NECROSIS FACTOR (TNF) BLOCKER
Hulio is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with moderate to severe rheumatoid arthritis. Hulio is also indicated to treat juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease in adults, ulcerative colitis, and plaque psoriasis. Hulio is also referred to by its drug name, adalimumab-fkjp.
Hulio is used as targeted therapy for adult rheumatoid arthritis. Hulio is a member of a class of drugs called tumor necrosis factor (TNF) blockers. Hulio is believed to work by blocking the activity of TNF, a substance that can cause inflammation and immune system diseases such as rheumatoid arthritis. Hulio is biologically similar to the FDA-approved drug Humira (adalimumab).
How do I take it?
Prescribing information states that Hulio is administered every other week.
Hulio comes in the form of a subcutaneous injection.
The FDA-approved label for Hulio lists common side effects including upper respiratory infections, headache, rash, and injection site reactions like redness, swelling, itching, and bruising.
Rare but serious side effects listed for Hulio include serious infections, cancer, severe allergic reaction, reactivation of a hepatitis B virus infection, heart failure, lupus-like syndrome, and demyelinating disease (such as multiple sclerosis or Guillain-Barre syndrome).
For more details about this treatment, visit:
Hulio — RxList
Hulio — European Medicines Agency